4/12/2012

GE Healthcare said initial results from two Phase III trials are promising for flutemetamol, an experimental PET imaging agent for Alzheimer's disease. In one study, findings on PET correlate with brain-autopsy data. In the other study, results are consistent with a known lack of brain amyloid in patients.

Related Summaries